The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6

Interleukin 6 (IL-6) is considered an important mediator of acute inflammatory responses. Moreover, IL-6 functions as a differentiation and growth factor of hematopoietic precursor cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts, and endothelial cells. IL-6 exhibits its action via a receptor complex consisting of a specific IL- 6 receptor (IL-6R) and a signal transducing subunit (gp130). Soluble forms of both receptor components are generated by shedding and are found in patients with various diseases such as acquired immune deficiency syndrome, rheumatoid arthritis, and others. The function of the soluble (s)IL-6R in vivo is unknown. Since human (h)IL-6 acts on human and murine target cells, but murine IL-6 on murine cells only, we constructed transgenic mice expressing the hsIL-6R. We report here that in the presence of hsIL-6R, mice are hypersensitized towards hIL-6, mounting an acute phase protein gene induction at significantly lower IL-6 dosages compared to control animals. Furthermore, in hsIL-6R transgenic mice, the detected acute phase response persists for a longer period of time. The IL-6/IL-6R complex prolongs markedly the Il- 6 plasma half-life. Our results reinforce the role of the hsIL-6R as an agonistic protein, help to understand the function of the hsIL-6R in vivo, and highlight the significance of the receptor in the induction of the acute phase response.

• Publication year

  1996

• Venue

  Journal of Experimental Medicine

• Publication date

  1996-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/JEM.183.4.1399PMID 8666898PMCID 2192475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B Gene

  1997cited by this paper
• A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.

  1995cited by this paper
• gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells.

  1995cited by this paper
• Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors

  1995cited by this paper
• Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption.

  1995cited by this paper
• Cytokine receptor signalling

  1995cited by this paper
• Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, Poznań, Poland

  1995cited by this paper
• A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene.

  1995cited by this paper
• Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.

  1995cited by this paper
• Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.

  1995cited by this paper
• Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor.

  1995cited by this paper
• Soluble interleukin 6 receptor is biologically active in vivo.

  1995cited by this paper
• Circulating interleukin-6 receptor in patients with sepsis syndrome.

  1995cited by this paper
• Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor.

  1994cited by this paper
• Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

  1994cited by this paper
• The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.

  1994cited by this paper
• Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction.

  1994cited by this paper
• Soluble receptors for cytokines and growth factors: generation and biological function.

  1994influential reference
• Cytokine signal transduction.

  1994cited by this paper
• Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

  1994cited by this paper
• Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification.

  1993cited by this paper
• Interleukin-6 in biology and medicine.

  1993cited by this paper
• Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding.

  1993cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

  1993cited by this paper
• The soluble interleukin‐6 receptor is generated by shedding

  1993cited by this paper
• Differential shedding of the two subunits of the interleukin‐6 receptor

  1993cited by this paper
• Increased osteoclast development after estrogen loss: mediation by interleukin-6.

  1992cited by this paper
• Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.

  1992cited by this paper
• The CD27 membrane receptor, a lymphocyte‐specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis

  1992cited by this paper
• Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.

  1992cited by this paper
• Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

  1992cited by this paper
• Dynamics of interleukin-6 internalization and degradation in rat hepatocytes.

  1992cited by this paper
• Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

  1992cited by this paper
• Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor.

  1992cited by this paper
• Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

  1992cited by this paper
• Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.

  1992cited by this paper
• Interferon‐γ and Interleukin‐4 down‐regulate soluble CD14 release in human monocytes and macrophages

  1992cited by this paper
• Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor.

  1992cited by this paper
• Increased osteoclast development after estrogen loss: mediation by interleukin-6

  1992cited by this paper
• Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders.

  1991cited by this paper
• Interleukin-6 in clinical medicine

  1991cited by this paper
• Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

  1990cited by this paper
• Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms

  1990cited by this paper
• Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase.

  1990cited by this paper
• Increased plasma levels of interleukin-6 in sepsis.

  1989cited by this paper
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper
• The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

  1989cited by this paper
• Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis.

  1989cited by this paper
• Increased plasma levels of interleukin-6 in sepsis [see comments]

  1989cited by this paper
• Soluble cytokine receptors are present in normal human urine

  1989cited by this paper
• Involvement of IL-6 in mesangial proliferative glomerulonephritis.

  1989cited by this paper
• The acute phase response: an overview.

  1988cited by this paper
• Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.

  1988cited by this paper
• Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

  1987cited by this paper
• The induction of ornithine decarboxylase by the tumor promoter TPA is controlled at the post-transcriptional level in murine Swiss 3T3 fibroblasts.

  1987cited by this paper
• Production of hybridoma growth factor by human monocytes

  1987cited by this paper
• A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

  1983cited by this paper
• The nucleotide sequence of the human β-globin gene

  1980cited by this paper
• The nucleotide sequence of the human beta-globin gene.

  1980cited by this paper

• Insights from Interleukin-6 trans-signaling and implications for the control of cytokine activity.

  2026cites this paper
• Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial Fibrillation

  2025cites this paper
• The social ambivalence and disease model: Childhood trauma as an antecedent factor linking spousal ambivalence to inflammation.

  2025cites this paper
• IL-6 trans-signaling in cystic fibrosis bronchial cells potentiates TNF-α-driven ICAM-1 expression

  2025cites this paper
• Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy

  2025cites this paper
• Implications of EBV-Encoded and EBV-Related miRNAs in Tumors.

  2025cites this paper
• The Role of Exerkines in the Treatment of Knee Osteoarthritis: From Mechanisms to Exercise Strategies

  2025cites this paper
• Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

  2024cites this paper
• No Association of Polymorphisms in the Genes Encoding Interleukin-6 and Interleukin-6 Receptor Subunit Alpha with the Risk of Keloids in Polish Patients

  2024cites this paper
• Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease

  2024cites this paper
• The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions

  2024cites this paper
• Cross-Sectional and Longitudinal Associations of Serum LRG1 with Severity and Prognosis Among Adult Community-Acquired Pneumonia Patients

  2024cites this paper
• An update of murine models and their methodologies in immune-mediated joint damage and pain research.

  2024cites this paper
• Carcinogenic mechanisms of virus-associated lymphoma

  2024cites this paper
• Interleukin-6 in non-infectious uveitis: Biology, experimentalevidence and treatment strategies.

  2024cites this paper
• Targeting IL-6 trans-signalling: past, present and future prospects

  2023cites this paper
• The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets

  2023cites this paper
• Role of interleukin 6 and its soluble receptor on the diffusion barrier dysfunction of alveolar tissue

  2023cites this paper
• Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases.

  2023cites this paper
• IL-6 and its role in IgA nephropathy development.

  2022cites this paper
• Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

  2022cites this paper
• Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization

  2022cites this paper
• IL‐6 signaling in acute exercise and chronic training: Potential consequences for health and athletic performance

  2022cites this paper
• A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients

  2022cites this paper
• Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody

  2022cites this paper
• HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer

  2022cites this paper
• Depression and interleukin-6 signaling: A Mendelian Randomization Study.

  2021cites this paper
• Selective Inhibition of IL-6 Trans-Signaling Has No Beneficial Effect on the Posttraumatic Cytokine Release after Multiple Trauma in Mice

  2021cites this paper
• Pharmacological Inhibition of BACE1 Suppresses Glioblastoma Growth by Stimulating Macrophage Phagocytosis of Tumor Cells

  2021cites this paper
• A Nonlethal Murine Flame Burn Model Leads to a Transient Reduction in Host Defenses and Enhanced Susceptibility to Lethal Pseudomonas aeruginosa Infection

  2021cites this paper
• Natural Glycoforms of Human Interleukin 6 Show Atypical Plasma Clearance

  2021cites this paper
• Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19

  2021cites this paper
• Blocking only the bad side of IL-6 in inflammation and cancer.

  2021cites this paper
• Inhibition of BACE1 Facilitates Macrophage-based Immunotherapy to Suppress Malignant Growth of Glioblastoma

  2020cites this paper
• Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency

  2020cites this paper
• A roadmap to target interleukin-6 in osteoarthritis

  2020cites this paper
• Molecular dynamics analysis of the binding of human interleukin‐6 with interleukin‐6 α‐receptor

  2020cites this paper
• Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

  2020cites this paper
• Multifaceted effects of soluble human CD6 in experimental cancer models

  2020cites this paper
• IL-15Rα membrane anchorage in either cis or trans is required for stabilization of IL-15 and optimal signaling

  2019influential citation
• Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines

  2019cites this paper
• Stem Cells from Human Extracted Deciduous Teeth Expanded in Foetal Bovine and Human Sera Express Different Paracrine Factors After Exposure to Freshly Prepared Human Serum.

  2019cites this paper
• The roles of EBV-encoded microRNAs in EBV-associated tumors.

  2019cites this paper
• Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs

  2019cites this paper
• Egr-1 functions as a master switch regulator of remote ischemic preconditioning-induced cardioprotection

  2019cites this paper
• Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

  2019cites this paper
• ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer

  2019cites this paper
• Moderate correlation between systemic IL‐6 responses and CRP with trough concentrations of voriconazole

  2018cites this paper
• Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis

  2018cites this paper
• The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology

  2018cites this paper
• Edinburgh Explorer The interleukin-6 receptor as a target for prevention of coronary heart disease

  2018cites this paper
• In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease

  2018cites this paper
• Impact of fasting followed by short-term exposure to interleukin-6 on cytochrome P450 mRNA in mice.

  2018cites this paper
• Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

  2018cites this paper
• A pilot study to profile salivary angiogenic factors to detect head and neck cancers

  2018cites this paper
• SorLA in Interleukin-6 Signaling and Turnover

  2017cites this paper
• The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis

  2017cites this paper
• EBV‑BART‑6‑3p and cellular microRNA‑197 compromise the immune defense of host cells in EBV‑positive Burkitt lymphoma.

  2017cites this paper
• Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature

  2017cites this paper
• The role of interleukin‐6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis

  2017cites this paper
• Autologous serum supplement favours in vitro regenerative paracrine factors synthesis

  2017cites this paper
• The role of miR-23a~24~27a cluster in the pathogenesis of treatment resistant rheumatoid arthritis

  2017cites this paper
• The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.

  2017cites this paper
• Programmed cell senescence: role of IL-6 in the pituitary.

  2017cites this paper
• Selected cytokine pathways in rheumatoid arthritis

  2017cites this paper
• Amigo2-upregulation in Tumour Cells Facilitates Their Attachment to Liver Endothelial Cells Resulting in Liver Metastases

  2017cites this paper
• Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression.

  2017cites this paper
• Characterization of the in vivo immunomodulatory properties of CD5 and CD6

  2017cites this paper
• Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures

  2016cites this paper
• Therapeutic response in human cancers : the dual role of STAT signalling

  2016cites this paper
• The interleukin-6 receptor as a target for prevention of coronary heart disease : a mendelian randomisation analysis

  2016cites this paper
• IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection

  2016cites this paper
• Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation

  2016cites this paper
• The biology behind interleukin-6 targeted interventions

  2016cites this paper
• Assessing pain and inflammation in arthritis using novel imaging methods

  2016cites this paper
• IL-6 pathway in the liver: From physiopathology to therapy.

  2016cites this paper
• Interleukin-6 role in head and neck squamous cell carcinoma progression

  2016cites this paper
• The Biology of Interleukin-6, a Major Target in Anti-Inflammatory Therapies

  2016cites this paper
• Expression And Functions Of Il-24 And Socs3 In Pseudomonas Aeruginosa Keratitis In A C57bl/6 Mouse Model

  2016cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2015cites this paper
• The soluble interleukin-6 receptor and related proteins.

  2015cites this paper
• Fetal and early neonatal interleukin-6 response.

  2015cites this paper
• Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.

  2015cites this paper
• Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.

  2015cites this paper
• Protection of intestinal injury during heat stroke in mice by interleukin‐6 pretreatment

  2015influential citation
• IL-6 as a keystone cytokine in health and disease

  2015cites this paper
• IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age

  2015cites this paper
• IL-6 Plays a Crucial Role in HBV Infection

  2015cites this paper
• Development and optimization of receptor fusion proteins for the inhibition of IL-6-type cytokines in vivo

  2015cites this paper
• Refining a ‘toolkit’ for objective assessment of pain and stress in ruminants

  2015cites this paper
• Human cancer growth and therapy in immunodeficient mouse models.

  2014cites this paper
• The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma

  2014cites this paper
• IL12Rβ1ΔTM Is a Secreted Product of il12rb1 That Promotes Control of Extrapulmonary Tuberculosis

  2014cites this paper
• Increased levels of the soluble receptor of Interleukin-6 in patients with preeclampsia compared to normotensive pregnant women

  2014cites this paper
• Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure

  2014cites this paper
• Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.

  2014influential citation
• The role of visfatin on the regulation of inflammation and apoptosis in the spleen of LPS-treated rats

  2014cites this paper
• STAT-3 Activation by Differential Cytokines Is Critical for Human In Vivo–Generated Plasma Cell Survival and Ig Secretion

  2013cites this paper
• Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.

  2013cites this paper
• Effects of Central and Peripheral Administration of Neuropeptide S on the Level of Serum Proinflammatory Cytokines in Pigs

  2013cites this paper